SUMMARY

JS002 Competitive Landscape in China

Generic
Name

Brand
Name

Company

China
Filing
Status

Key
MOA

Proposed
Indications

Retail Price

(RMB)

IND

NDA

Approved

Submitted

Time

Time

NDA

Application

Number

Evolocumab

Repatha

Amgen

NDA

Approved

Anti-PCSK9

Alirocumab

Praluent

Sanofi-
Aventis.

Phase III

Anti-PCSK9

Homozygous
Familial
Hypercholestero
lemia

Hypercholestero
lemia

N.A.*

2015.1

2017.10

JXSS1700014

N.A.

2015.12

N.A.

N.A.

JS002

Junshi

Phase I

Anti-PCSK9 Hypercholestero

lemia

N.A.

2017.8

N.A.

N.A.

IBI306

Innovent

Phase I

Anti-PCSK9

Hypercholestero
lemia

N.A.

2017.9

N.A.

N.A.

AK-102

Akeso,

Dawnrays

Phase I

Anti-PCSK9

Hypercholestero
lemia

N.A.

2018.4

N.A.

N.A.

SHR-1209

Hengrui

Phase I

Anti-PCSK9

CVI-LM001

Pharmaceuticals Phase I

Anti-PCSK9

CVI

Hypercholestero
lemia

Hypercholestero
lemia

Category

Imported
therapeutic
biologics

Imported
therapeutic
biologics

Therapeutic

biologics
category 1

Therapeutic
biologics
category 1

Therapeutic
biologics
category 1

Therapeutic
biologics
category 1

N.A.

2018.6

N.A.

N.A.

N.A.

2016.3

N.A.

N.A.

Chemical drug
category 1.1

Note: All of the products are not included in the NRDL or PRDL.

UBP1213 Competitive Landscape in China

Generic
Name

Brand
Name

Company

Belimumab

Benlysta

GSK

China
Filing
Status

NDA

submission

Key
MOA

Proposed
Indications

Retail Price

(RMB)

IND

NDA 

Approved

Submitted

Time

Time

NDA

Application

Number

Category

Anti-BLyS

SLE

N.A.

2014.8

2018.4

JXSS1800005
JXSS1800006

Imported
therapeutic
biologics

UBP1213

Junshi

Phase I

Anti-BLyS

SLE

N.A.

2016.10

N.A.

N.A.

Therapeutic

biologics
category 1

Note: All of the products are not included in the NRDL or PRDL. Only fully human and humanized BLyS inhibitors

are listed.

– 5 –

